Standard Biotools LAB

Standard Biotools Inc. · Nasdaq · Pharmaceutical Preparations

$0.63+3.44%close on Nov. 20, 2026 · volume 2.8M · Yahoo Finance

Price, last 64 sessions

$0.60$0.70Sept. 2026Oct. 2026Nov. 2026
Aug. 24, 2026 to Nov. 20, 2026 · high $0.77 · low $0.54 · SEC filing, placed when SEC released it

Our coverage

Insider buying and selling

DateInsiderTradeSharesAvg. priceValue
Nov. 5, 2026Thomas D. Carey
director
Bought75,000$0.63$46,898

Open-market purchases and sales reported on SEC Form 4 filed since July 24, 2026; grants, option exercises and shares withheld for tax aren't shown. A trade under a 10b5-1 plan was scheduled in advance. Where a filing was amended, the amendment's figures are shown.

Recent SEC filings

All 29 →
  • 425Nov. 19, 2026, 5:01 p.m. ETView on SEC.gov
  • 8-KNov. 19, 2026, 5 p.m. ETView on SEC.govOur explainer

    Departure/appointment of directors or officers · Submission of matters to a vote of security holders · Regulation FD disclosure · Financial statements and exhibits

    AI summary, unreviewedStandard BioTools stockholders approve Treeline merger share issuance, 1-for-20 to 1-for-40 reverse split and Mass Cytometry sale

  • 425Nov. 16, 2026, 4:30 p.m. ETView on SEC.gov
  • 8-KNov. 16, 2026, 4:27 p.m. ETView on SEC.gov

    Other events

    AI summary, unreviewedStandard BioTools 8-K supplements Treeline merger proxy after 15 demand letters and two New York complaints; Centerview values company at $1.14 per share vs. $0.62 pre-filing market cap

  • SCHEDULE 13G/ANov. 16, 2026, 4 p.m. ETView on SEC.gov
  • 4Nov. 5, 2026, 5:36 p.m. ETView on SEC.gov
  • 10-QNov. 3, 2026, 4:45 p.m. ETView on SEC.gov
  • 425Nov. 3, 2026, 8:26 a.m. ETView on SEC.gov